163 related articles for article (PubMed ID: 3087269)
1. [Treatment of advanced cancer of the prostate with an analog of LHRH, buserelin].
Wenderoth UK; Jacobi GH
Ann Urol (Paris); 1986; 20(2):95-7. PubMed ID: 3087269
[TBL] [Abstract][Full Text] [Related]
2. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
[No Abstract] [Full Text] [Related]
3. Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer.
Huhtaniemi I; Venho P; Jacobi G; Rannikko S
J Androl; 1991; 12(1):46-53. PubMed ID: 1901309
[TBL] [Abstract][Full Text] [Related]
4. Influence of LH-RH agonists on the growth and hormonal environment of breast and prostate cancer.
Nicholson RI; Walker KJ
Chemioterapia; 1985 Jun; 4(3):249-51. PubMed ID: 3161643
[TBL] [Abstract][Full Text] [Related]
5. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
6. [Clinical experience with single and multiple subcutaneous administration of LHRH analog Buserelin (Hoe 766) in prostatic carcinoma: endocrinological study of optimum subcutaneous doses].
Niijima T; Isurugi K; Kawabe K; Kinoshita K; Asano M; Nakauchi K; Fujita K; Nishimura Y; Nitoh H; Yokoyama M
Hinyokika Kiyo; 1988 Jul; 34(7):1297-307. PubMed ID: 2459944
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of prostatic cancer with intranasal administration of LHRH analog, Buserelin (Hoe 766) study of the optimum dosage of intranasal application].
Niijima T; Kishimoto T; Shimazaki J; Yoshida O; Isurugi K
Hinyokika Kiyo; 1988 Jul; 34(7):1309-19. PubMed ID: 3140622
[TBL] [Abstract][Full Text] [Related]
8. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
9. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of prostatic cancer with an LH-RH analog].
Fuse H; Zama S; Akimoto S; Shimazaki J; Murakami S; Igarashi T
Hinyokika Kiyo; 1986 Aug; 32(8):1113-9. PubMed ID: 3098063
[TBL] [Abstract][Full Text] [Related]
11. Long term follow-up of patients with advanced prostatic cancer treated with nasal buserelin.
Falkson CI; Falkson G; Falkson HC
Ann Oncol; 1991 Apr; 2(4):303-4. PubMed ID: 1907843
[TBL] [Abstract][Full Text] [Related]
12. Metastatic prostate cancer under long term pernasal buserelin or intramuscular decapeptyl depot treatment.
Wenderoth UK; Spindler HW; Ehrenthal W; von Wallenberg H; Happ J; Jacobi GH
Prog Clin Biol Res; 1987; 243A():207-20. PubMed ID: 2958851
[No Abstract] [Full Text] [Related]
13. [1st clinical results of the treatment of locally advanced prostatic cancer with a powerful LH-RH analog: buserelin acetate].
Nagel R; Borgmann V; Al-Abadi H; Schmidt-Gollwitzer M
J Urol (Paris); 1983; 89(9):669-76. PubMed ID: 6425419
[TBL] [Abstract][Full Text] [Related]
14. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
Oka H; Negoro H; Sugino Y; Iwamura H; Moroi S; Kawakita M
Hinyokika Kiyo; 2003 Sep; 49(9):521-5. PubMed ID: 14598689
[TBL] [Abstract][Full Text] [Related]
15. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
Lukkarinen O; Kontturi M
Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
[TBL] [Abstract][Full Text] [Related]
16. [Buserelin therapy in postmenopausal patients with advanced breast carcinoma].
Vici P; Veltri E; Carpano S; Di Lauro L; Lopez M
Clin Ter; 1991 Feb; 136(3):195-9. PubMed ID: 1827382
[TBL] [Abstract][Full Text] [Related]
17. Results obtained in the treatment of prostate cancer patients with Zoladex.
Williams G; Kerle DJ; Roe SM; Yeo T; Bloom SR
Prog Clin Biol Res; 1985; 185A():287-95. PubMed ID: 3162175
[No Abstract] [Full Text] [Related]
18. A long term follow-up of patients with advanced prostatic cancer treated with buserelin.
Waxman JH; Hendry WF; Whitfield HN; Oliver RT
Prog Clin Biol Res; 1985; 185A():271-7. PubMed ID: 3929266
[TBL] [Abstract][Full Text] [Related]
19. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
Hjertberg H; Varenhorst E; Svensson M; Kågedal B; Nordenskjöld B
Acta Oncol; 1988; 27(4):361-4. PubMed ID: 2974290
[TBL] [Abstract][Full Text] [Related]
20. The first clinical use of depot buserelin for advanced prostatic carcinoma.
Waxman JH; Sandow J; Man A; Barnett MJ; Hendry WF; Besser GM; Oliver RT; Magill PJ
Cancer Chemother Pharmacol; 1986; 18(2):174-5. PubMed ID: 3098445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]